About AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited is the Indian subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, and forms part of a global, science-led, patient-focused biopharmaceutical enterprise with a balanced presence across regions and leadership in Oncology, Biopharmaceuticals (Cardiovascular, Renal & Metabolism; Respiratory & Immunology) and Rare Disease. Marking 45 years of operations in India, the company highlights a legacy of “reimagining healthcare” through life‑changing medicines across multiple therapy areas. Its core business spans manufacture, distribution and marketing of pharmaceutical products, alongside clinical trial services provided to an overseas group company; its product mix includes tablets, injectables and inhalation therapies.

AstraZeneca Pharma India Limited’s Key Brands 

Key brands in India include Tagrisso, Lynparza, Imfinzi, Enhertu and Imjudo, reflecting a strong oncology focus and expanding presence in other specialist disease areas.

AstraZeneca Pharma India Limited’s Business Segments

• Operating model: Single reportable business segment (pharmaceutical products and related services).
• Revenue by industry vertical (therapy area): FY 2024–25 sales by therapy area totaled Rs 16,084 million, comprising Oncology Rs 11,171 million (69.5%), Biopharmaceuticals Rs 4,881 million (30.3%) and Rare Disease Rs 32 million (0.7%) .
• Revenue by products/services: FY 2024–25 revenue from operations was Rs 17,162.9 million, including sale of pharmaceutical products (tablets Rs 8,984.6 million; injectables Rs 6,827.2 million; inhalation Rs 272.5 million), services to related parties for clinical trials Rs 1,048.6 million, and income from grant of exclusive distribution rights Rs 30 million. 

AstraZeneca Pharma India Limited Key Management

• Shilpa Divekar Nirula, Chairperson.
• Sanjeev Kumar Panchal, Managing Director.
• Bhavana Agrawal, Director & Chief Financial Officer.

Latest Updates on AstraZeneca Pharma India Limited

• Portfolio and launches: Enhertu, launched in 2024, surpassed Rs 2,000 million in its first year and is expanding into additional HER2‑associated tumors; Imjudo was introduced for hepatocellular carcinoma. Imfinzi continued strong growth; Tagrisso remains a leading oncology brand, while Lynparza faced value erosion post‑2024 loss of exclusivity with multiple generics entering the market.
• Market performance: In FY 2024–25 the company was the fastest‑growing among top‑ranked IPM companies, improving its revenue ranking to #40 from #44 in the prior year .
• Operations: The company decided to exit its manufacturing site, with operations expected to cease during FY 2025–26; useful lives of related assets were revised, impacting FY 2024–25 depreciation and amortisation.
• Approvals and access: Since 2023, there have been 14 new medicines and indication approvals, and access‑to‑healthcare programmes reached roughly 200,000 people.
• People and recognition: Awards included ‘Silver’ for Best Employer for Women (Small Category) at the ASSOCHAM 5th Diversity & Inclusion Excellence Awards 2024 and the Diversity and Inclusion Award 2024 at the 57th OPPI Annual Day.
• Leadership transition: The Managing Director’s Statement notes assumption of the role of Country President and Managing Director effective July 1, 2025.